causal
Improving treatment erodes screening benefit
Every mammographic randomized trial likely overstates current benefit because treatments have improved dramatically since the trials (around 30 new breast cancer drugs, better surgery, radiation, scanning, and supportive care); as treatment for advanced disease improves, the differential effect screening exploits shrinks, eroding whatever benefit existed.
causalpending
Speaker
Vinay PrasadEvidence Quote
“It's a different disease than it was in 1985, thankfully. And that, in my opinion, will erode whatever benefit of screening was there in a study that was finished in 1985.”
Created: 6/13/2026, 12:15:40 AM
Your notes
Loading notes...